Core Insights - Bluejay Diagnostics, Inc. announced the acceptance of an abstract for the Symphony IL-6 Test at the SAEM Annual Meeting, highlighting its potential in sepsis management [1][2] - The SYMON-I study results will be presented, focusing on IL-6 as a prognostic biomarker for mortality in sepsis patients [1][4] Company Overview - Bluejay Diagnostics is focused on developing rapid and accessible biomarker testing, with its lead product being the Symphony IL-6 Test for sepsis triage [5] - The Symphony IL-6 Test aims to provide results in approximately 20 minutes, assisting healthcare professionals in making timely treatment decisions [5] Clinical Study Details - The SYMON Clinical Study Program includes SYMON-I and SYMON-II, with SYMON-I being a pilot study assessing IL-6 levels related to various mortality endpoints [4] - SYMON-II is a pivotal study intended to validate SYMON-I outcomes and support a 510(k) application to the FDA [4] Presentation Information - The presentation titled "Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study (SYMON I)" will take place on May 14, 2025, by presenters John H. Lee, M.D., Ph.D. and Nathan Shapiro, M.D. [3]